PharmaCorp Rx (TSXV:PCRX) EV-to-EBIT : -17.59 (As of Mar. 02, 2025)

View and export this data going back to 2022. Start your Free Trial

What is PharmaCorp Rx EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PharmaCorp Rx's Enterprise Value is C$37.00 Mil. PharmaCorp Rx's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was C$-2.10 Mil. Therefore, PharmaCorp Rx's EV-to-EBIT for today is -17.59.

The historical rank and industry rank for PharmaCorp Rx's EV-to-EBIT or its related term are showing as below:

TSXV:PCRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.65 Med: -14.81 Max: 7.31
Current: -17.59

During the past 3 years, the highest EV-to-EBIT of PharmaCorp Rx was 7.31. The lowest was -26.65. And the median was -14.81.

TSXV:PCRX's EV-to-EBIT is ranked worse than
100% of 180 companies
in the Diversified Financial Services industry
Industry Median: 4.97 vs TSXV:PCRX: -17.59

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. PharmaCorp Rx's Enterprise Value for the quarter that ended in Sep. 2024 was C$55.26 Mil. PharmaCorp Rx's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was C$-2.10 Mil. PharmaCorp Rx's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -3.81%.

PharmaCorp Rx EV-to-EBIT Historical Data

The historical data trend for PharmaCorp Rx's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaCorp Rx EV-to-EBIT Chart

PharmaCorp Rx Annual Data

Trend

Dec21

Dec22

Dec23

EV-to-EBIT

-37.77

-10.75

PharmaCorp Rx Quarterly Data
	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EV-to-EBIT	Get a 7-Day Free Trial								-19.43	-10.75	-8.90	0.37	-26.28

Competitive Comparison of PharmaCorp Rx's EV-to-EBIT

For the Shell Companies subindustry, PharmaCorp Rx's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCorp Rx's EV-to-EBIT Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, PharmaCorp Rx's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PharmaCorp Rx's EV-to-EBIT falls into.

PharmaCorp Rx EV-to-EBIT Calculation

PharmaCorp Rx's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	37.002	/	-2.103
	=	-17.59

PharmaCorp Rx's current Enterprise Value is C$37.00 Mil.
PharmaCorp Rx's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.10 Mil.

PharmaCorp Rx (TSXV:PCRX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

PharmaCorp Rx's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2024 )	=	EBIT	/	Enterprise Value (Q: Sep. 2024 )
	=	-2.103	/	55.26226
	=	-3.81 %

PharmaCorp Rx's Enterprise Value for the quarter that ended in Sep. 2024 was C$55.26 Mil.
PharmaCorp Rx's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.10 Mil.

PharmaCorp Rx EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of PharmaCorp Rx's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaCorp Rx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » PharmaCorp Rx Inc (TSXV:PCRX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

303 Wellman Lane, Suite 203, Saskatoon, SK, CAN, S7T 0J1

Website

PharmaCorp Rx Inc foremerly Proton Capital Corp is a Capital Pool Company. The principal business of the company is to identify and evaluate assets or businesses with a view to potentially acquiring them or interest therein by completing a purchase transaction, by exercising an option, or by any concomitant transaction.